Denali Therapeutics Inc [DNLI] stock is trading at $22.23, up 2.02%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNLI shares have gain 8.02% over the last week, with a monthly amount glided 1.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $31. Previously, Robert W. Baird started tracking the stock with Outperform rating on January 07, 2025, and set its price target to $31. On January 03, 2025, William Blair initiated with a Outperform rating. Stifel upgraded its rating to a Buy but stick to its price target of $37 on December 16, 2024. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 07, 2024. In a note dated December 13, 2023, Citigroup initiated an Buy rating and provided a target price of $32 on this stock.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $14.56 and $33.33 over the past year. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $22.23 at the most recent close of the market. An investor can expect a potential return of 55.2% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Denali Therapeutics Inc [NASDAQ:DNLI] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.02% with Operating Profit Margin at 1.65%, Pretax Profit Margin comes in at 1.4%, and Net Profit Margin reading is 1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.62 points at the first support level, and at 21.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.56, and for the 2nd resistance point, it is at 22.88.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 9.98. On the other hand, the Quick Ratio is 9.98, and the Cash Ratio is 1.04.
Transactions by insiders
Recent insider trading involved Ho Carole, Chief Medical Officer, that happened on Jan 06 ’25 when 12255.0 shares were sold. Chief Medical Officer, Ho Carole completed a deal on Jan 07 ’25 to sell 2907.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 12255.0 shares on Jan 06 ’25.
